Lingvay, I;
Brown-Frandsen, K;
Colhoun, HM;
Deanfield, J;
Emerson, SS;
Esbjerg, S;
Hardt-Lindberg, S;
... Ryan, DH; + view all
(2023)
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
Obesity
, 31
(1)
pp. 111-122.
10.1002/oby.23621.
Preview |
PDF
Semaglutide for cardiovascular event reduction.pdf - Published Version Download (1MB) | Preview |
Abstract
Objective: This paper describes the baseline characteristics of the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the largest cardiovascular (CV) outcome studies in the field of obesity, which evaluates the effect of semaglutide versus placebo on major CV events. Methods: SELECT enrolled individuals with overweight or obesity without diabetes, with prior myocardial infarction, stroke, and/or peripheral artery disease. This study reports participants' baseline characteristics in the full study population and subgroups defined by baseline glycated hemoglobin (HbA1c; <5.7%, ≥5.7 to <6.0%, ≥6.0 to <6.5%), baseline waist to height ratio tertile, and qualifying prior CV event or condition. Results: The study enrolled 17,605 participants (72.5% male) with an average (SD) age of 61.6 (8.9) years and BMI of 33.34 (5.04) kg/m2. The most common prior CV event was myocardial infarction (76.3% of participants), followed by stroke (23.3%) and peripheral artery disease (8.6%). Furthermore, 24.3% had a heart failure diagnosis. Two-thirds of participants (66%) had HbA1c in the prediabetes range (5.7%-6.4%). Across groups of increasing HbA1c, prevalence of all CV risk factors increased. Conclusions: The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.
Type: | Article |
---|---|
Title: | Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics |
Location: | United States |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1002/oby.23621 |
Publisher version: | https://doi.org/10.1002/oby.23621 |
Language: | English |
Additional information: | © 2022 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
Keywords: | Female, Humans, Male, Middle Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Myocardial Infarction, Obesity, Overweight, Peripheral Arterial Disease, Stroke |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Clinical Science |
URI: | https://discovery.ucl.ac.uk/id/eprint/10162471 |
Archive Staff Only
![]() |
View Item |